Brief: Definium Therapeutics Phase 3 Voyage Study Of DT120 ODT Met Primary & Key Secondary Efficacy Endpoints
12/08/2026 12:00
BRIEF-Definium Therapeutics Phase 3 Voyage Study Of DT120 ODT Met Primary & Key Secondary Efficacy Endpoints Aug 12 (Reuters) - Definium Therapeutics Inc DFTX.O:
DEFINIUM THERAPEUTICS: PHASE 3 VOYAGE STUDY OF DT120 ODT MET PRIMARY & KEY SECONDARY EFFICACY ENDPOINTS
DEFINIUM THERAPEUTICS: DT120 ODT GENERALLY WELL TOLERATED IN STUDY, NO NEW SAFETY SIGNALS INCLUDING NO SUICIDALITY SIGNAL
DEFINIUM THERAPEUTICS: PARTICIPANTS ON DT120 ODT ACHIEVED STATISTICALLY SIGNIFICANT REDUCTION IN HAMILTON ANXIETY RATING SCALE SCORE
Further company coverage: DFTX.O
((Reuters.Briefs@thomsonreuters.com;))